Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03149991 · ClinicalTrials.gov registry record · Phase 4
A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
NCT03149991: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT03149991 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03149991, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
Study Summary
This is a multi-site, double-blind, placebo-controlled study of the acute efficacy of brexpiprazole or placebo in combination with intranasal ketamine added to ongoing, stable, and adequate antidepressant therapy (ADT) in the treatment of adults with Major Depressive Disorder with Treatment Resistant Depression.
Interventions
- DRUG Placebo
- DRUG Ketamine
- DRUG Brexpiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2017-09-14 |
| Est. Completion | 2019-06-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03149991
The ClinicalTrials.gov registry entry for NCT03149991 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03149991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03149991 about?
NCT03149991 is a clinical study titled "A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)". This is a multi-site, double-blind, placebo-controlled study of the acute efficacy of brexpiprazole or placebo in combination with intranasal ketamine added to ongoing, stable, and adequate antidepressant therapy (ADT) in the treatment of adults with Major Depressive Disorder with Treatment Resistan...
What is the current status of trial NCT03149991?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2017-09-14. Estimated completion is 2019-06-15.
What interventions are being tested in trial NCT03149991?
The interventions under investigation include: Placebo (DRUG), Ketamine (DRUG), Brexpiprazole (DRUG).
Who is sponsoring clinical trial NCT03149991?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.